Abstract
Chronic inflammatory bowel disease (IBD) carries a high burden of disease for individuals and global healthcare systems. Clinical suspicion of IBD requires early initiation of the diagnostic work-up and referral to a pediatric gastroenterology center. Current guidelines for the treatment of pediatric IBD recommend the selection of individual treatment regimens based on risk stratification of disease severity and activity. Regular therapeutic monitoring should be performed according to the treat-to-target approach, with fecal calprotectin being a reliable, noninvasive biomarker for IBD activity. Early and risk-adapted treatment can have a positive influence on the disease course, thereby enabling normal physical, social, and emotional development of the child. This long-term goal can only be achieved by promoting close cooperation between the local pediatrician and the pediatric gastroenterologist and providing long-term multidisciplinary care of the growing patient beyond childhood.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 0026-9298 |
Sprache: | Deutsch |
Dokumenten ID: | 111656 |
Datum der Veröffentlichung auf Open Access LMU: | 02. Apr. 2024, 07:28 |
Letzte Änderungen: | 02. Apr. 2024, 07:28 |